Molecular Insight Pharma - Comparative Multiple Analysis

Molecular Insight Pharma (Comparative Multiple Analysis)


Notes on the Comparative Multiple Analysis of Molecular Insight Pharma

WikiWealth compares Molecular Insight Pharma's revenue, EBITDA, and EBIT multiples to their peers in order to determine the appropriate fair valuation. Click in the top right corner to experiment with Molecular Insight Pharma's comparative analysis.

Notes from the analysis:

1. WikiWealth uses quantitative measures to determine the multiple range for Molecular Insight Pharma.
2. Free cash flow to the firm (FCF) multiple is free cash flow to equity holders plus interest owed to Molecular Insight Pharma's debt holders.
3. Multiples incorporate benefits due to economies of scale; WikiWealth compares absolute enterprise value multiples to competitor's multiples.
4. WikiWealth excludes outliers when calculating individual company multiples.

Helpful Information for Molecular Insight Pharma's Analysis

How does this work? The Comparative Investment Analysis determines the value of Molecular Insight Pharma by comparing Molecular Insight Pharma financial ratios, prices, growth rates, margins, etc. to those of relevant peer groups.

Value Investing Importance? This method is widely used by investment professionals to determine the correct price of investments, especially initial public offerings (IPOs). It is one element of WikiWealth's three Wall Street approaches used to determine the correct fair value of Molecular Insight Pharma.

See the Molecular Insight Pharma cash flow (DCF) analysis for a completely different approach that's popular on Wall Street for determining the value of an investment in Molecular Insight Pharma.

Also, see the Molecular Insight Pharma's buffett intrinsic valuation analysis for WikiWealth's attempt to replicate the investing formula's used by Warren Buffett and Molecular Insight Pharma's valuation conclusion for a quick summary.